Bone Biologics Corp (BBLG) Form 10-Q — Oct 26, 2026
Bone Biologics reported a Q3 2026 net loss of $617,651 with no revenue, bringing nine-month net loss to $2.16 million, and the 10-Q carries going-concern doubt with cash of $6.1 million expected to fund operations only through Q2 2027. The company disclosed a Nasdaq bid-price deficiency notice received September 10, 2026, giving it until March 9, 2027 to regain compliance with the $1 minimum bid rule; stockholders have approved a reverse split of 1-for-2 up to 1-for-10 as a potential cure.
Key figures
- Revenue
- 0
- Total Assets
- 6432445
- Cash Position
- 6088085
- Shares Outstanding
- 3389057
- Runway
- through Q2 2027
- Outstanding warrants
- 7639942
- Nasdaq compliance deadline
- March 9, 2027
- Unit price private placement
- 1.419
- Plausible reverse split range
- 1-for-2 to 1-for-10
- Net proceeds july 2026 private placement
- 2639667
- Gross proceeds july 2026 private placement
- 2997888
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.